Bisoprolol+pyridostgmine
ApprovedSmall molecule
Bisoprolol+pyridostgmine is one of 22 small molecule programs targeting Tachycardia. It is currently in Approved.
1
Indications
1
Total Trials
0
Active Trials
21
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
27 competitors in Tachycardia
#DrugCompanyPhaseTrials
1Epsom Salt
FFresenius Kabi Oncology Ltd.
Approved
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Approved
Inderal
WWyeth-Lederle Vaccines
Approved
Corlanor
AmgenPhase 3
Rapiblyk
AAultman Health Foundation
Approved
Brevibloc
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Lodosyn
LLaTonya J. Hickson
Phase 3
Beta Blocker
WWeill Medical College of Cornell University
Phase 3
Mestinon
UUnited BioPharma
Phase 2
Bisoprolol+pyridostgmine
SSeoul National University Hospital
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Bisoprolol+pyridostgmine. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details